PROCEDURE OF ACTIVATION OF THE CYTOLYTIC ACTIVITY OF THE LYMPHOCYTES USING ANTI-CD28 ANTIBODIES.

摘要

THE DEVELOPMENT OF THE CYTOLYTIC ACTIVITY OF THE LYMPHOCYTES CAN BE ENHANCED BY CONTACTING THE LYMPHOCYTES WITH THE ANTIBODY REAGENT WITH THE CD28 RECEPTOR, SUCH AS THE MONOCLONIC ANTIBODY 9.3. THE CYTOLYTIC ACTIVITY SO POTENTIATED IS A CD3 INDEPENDENT HETEROCONJUGATE SINCE THE OBJECTIVE WITH A CD3 ANTI-OBJECTIVE COMPOUND IS NOT REQUIRED. THE DEVELOPMENT OF CYTOLYTIC ACTIVITY CAN BE ENHANCED MORE BY ALSO CONTACTING LYMPHOCYTES WITH ANTIBODY REAGENT WITH ANTIBODY ANTI-CD2 OR WITH ANTIBODY IMMOBILIZED TO THE CD3 RECEPTOR, OR ALSO CONTACTING 2-LINPHOCYTES. THE CD28 RECEIVER MAY ADD TO THE SURFACE OF LYMPHOCYTES BY CROSS-LINKING THE ANTIBODY REAGENT TO SUCH RECEPTOR ON THE SURFACE OF LYMPHOCYTES. THIS TRANSVERSE JOINT MAY BE MADE USING A SECOND ANTIBODY REAGENT WITH ANTI-CD28 ANTIBODY. ANOTHER ASPECT OF THE PRESENT INVENTION IS CONSTITUTED A METHOD OF ADOPTION THERAPY TO TREAT CANCER IN A SUBJECT THAT INCLUDES THE STEPS OF: (1) CONTACTING THE IN VITRO LYMPHOCYTES WITH AN ANTIBODY REAGENT WITH THE CD28 RECEIVER TO POTENTIATE THE DEACTIVATION OF THE CD28 RECEIVER CYTOLYTICS OF LYMPHOCYTES TO PRODUCE LYMPHOCYTES PROVIDED WITH SUCH CYTOLYTIC ACTIVITY WHICH IS THE INDEPENDENT CD3 HETERO-CONJUGATE; AND (2) INTRODUCE THE CYTOLYTIC LYMPHOCYTES IN A SUBJECT TO KILL THE CANCER CELLS.